LACK OF EFFECT OF PANTOPRAZOLE ON THE PHARMACODYNAMICS AND PHARMACOKINETICS OF WARFARIN

被引：45

作者：

DUURSEMA, L

MULLER, FO

SCHALL, R

MIDDLE, MV

HUNDT, HKL

GROENEWOUD, G

STEINIJANS, VW

BLIESATH, H

机构：

[1] UNIV ORANGE FREE STATE,DEPT PHARMACOL,FARMOVS INST CLIN PHARMACOL & DRUG DEV,BLOEMFONTEIN 9300,SOUTH AFRICA

[2] BYK GULDEN LOMBERG GMBH,D-78467 CONSTANCE,GERMANY

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1995年 / 39卷 / 06期

关键词：

WARFARIN; PANTOPRAZOLE; PHARMACOKINETICS; PHARMACODYNAMICS; INTERACTION;

D O I：

10.1111/j.1365-2125.1995.tb05732.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Twenty-six healthy males took part in this double-blind, randomised, placebo-controlled, two-period, cross-over study. Pantoprazole (40 mg) (test) or placebo (reference) were administered once daily, for 8 days, with a 3 week washout period. A single oral dose of 25 mg warfarin sodium was co-administered with pantoprazole or placebo on Day 2 of each treatment period. The 90% confidence intervals for the 'test/reference' mean ratios of the excess AUC(0,168 h) of prothrombin time and AUC(0, 168 h) of factor VII, and of C-max, AUC and t(1/2) of both R- and S-warfarin fell within the equivalence range of 80% to 125%. These results suggest that pantoprazole does not alter the pharmacokinetics or pharmacodynamics of warfarin.

引用

页码：700 / 703

页数：4

共 15 条

[1]

Simon B., Moller P., Bliesath H., Et al., Single intravenous administration of the H+, K+‐ATPase inhibitor BY1023/SK&F96022 – inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man, Aliment Pharmac Ther, 4, pp. 239-245, (1990)

[2]

Simon B., Moller P., Hartmann M., Et al., Pentagastrin stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K+‐ATPase‐inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers, Z Gastroenterol, 28, pp. 443-447, (1990)

[3]

Moller P., Simon B., Khalil H., Lohmann R., Leucht M., Schneider A., Dose range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients, Z Gastroenterol, 30, pp. 771-775, (1992)

[4]

Tucker GT., The interaction of proton pump inhibitors with cytochromes P450, Aliment Pharmac Ther, 8, pp. 33-38, (1994)

[5]

de Mey C., Meineke I., Steinijans VW, Et al., Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction, Int J clin Pharmac Ther, 32, pp. 98-106, (1994)

[6]

Gugler R., Hartmann M., Rudi J., Et al., Lack of interaction of pantoprazole and diazepam in man, Gastroenterology, 102, (1992)

[7]

Schulz H.U., Hartmann M., Steinijans VW, Et al., Lack of influence of pantoprazole on the disposition kinetics of theophylline in man, Int J clin Pharmac Ther Toxicol, 29, pp. 369-375, (1991)

[8]

Middle MV, Moller FO, Schall R., Groenewoud G., Hundt HKL, No influence of pantoprazole on the pharmacokinetics of phenytoin, Int J clin Pharmac Ther Toxicol, (1995)

[9]

EEC Note for Guidance: Good clinical practice for trials on medicinal products in the European community, Pharmac Tox, 67, pp. 361-372, (1990)

[10]

Duursema L., Moller FO, Hundt HKL, Heyns A.P., Meyer BH, Luus HG, Model to detect warfarin‐drug interactions in man, Drug Investigation, 4, pp. 395-402, (1992)

← 1 2 →